Stocks · News reference
Arbutus Biopharma shares are trading higher after the company announced the filing of three international lawsuits seeking to enforce patent protecting LNP technology against Pfizer, BioNTech and certain or other affiliates.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 16, 2026, 1:08 PM
- Checked
- Jul 16, 2026, 1:08 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why Is Arbutus Biopharma Stock Gaining Friday?
Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.
Read original at benzingaArbutus Biopharma shares are trading higher after the company announced plans to commence a modified Dutch Auction tender offer to repurchase up to $230 million shares at no less than $5.00 per share and not more than $5.75 per share.
Read original at benzingaArbutus Biopharma Plans To Commence Modified Dutch Auction Tender Offer To Repurchase Up To $230M Of Common Shares At Purchase Price Of Between $5.00 And $5.75 Per Share In Cash
Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified "Dutch
Read original at benzinga